Cognition Disorders clinical trials at UCSF
1 in progress, 1 open to new patients
open to eligible people ages 65–85
The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease [AD]).
San Francisco, California and other locations